Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 711? excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 711? is a trademark of Sirigen Group Ltd.

Additional reported applications (for the relevant formats) include: blocking of CD4⁺ T cell activation^1,4,11, thymocyte costimulation³, in vitro and in vivo depletion^2,5-8, blocking of egg-sperm cell adhesion^1,4, immunohistochemical staining of acetone-fixed frozen sections^9,10, immunoprecipitation^1,2, and spatial biology (IBEX)^12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation.?Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin < 0.01 EU/?g).

1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
12. Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
13. Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed

1. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
2. Mogilenko DA, et al. 2020. Immunity. 54(1):99-115.e12. PubMed
3. Zhang P et al. 2019. Cell Rep. 27(11):3117-3123 . PubMed
4. Franks SE, et al. 2019. J Immunol. 202:3381. PubMed
5. Haertel E, et al. 2018. Eur J Immunol. 48:1001. PubMed
6. Jamison BL, et al. 2019. J Immunol. 203:48. PubMed
7. DeLong JH, et al. 2019. Immunohorizons. 3:13. PubMed
8. Bommireddy R, et al. 2020. Vaccines (Basel). 8:. PubMed
9. Gary EN, et al. 2021. iScience. 24(7):102699. PubMed
10. Wang Y, et al. 2021. Sci Rep. 1.429861111. PubMed
11. DeLong JH, et al. 2018. J Immunol. 200:1761. PubMed
12. Pereira JA, et al. 2020. Hum Mol Genet. 29:1253. PubMed
13. Hiebert P et al. 2018. Developmental cell. 46(2):145-161 . PubMed
14. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
15. Nelson CE et al. 2019. Cell Rep. 28(12):3092-3104 . PubMed
16. Lee SC et al. 2018. Cancer cell. 34(2):225-241 . PubMed
17. Cowan J, et al. 2016. Cell Rep. 14:1041-1048. PubMed
18. Pai CS, et al. 2020. Immunity. 50(2):477-492. PubMed
19. Fearon AE, et al. 2021. iScience. 24:103143. PubMed
20. Ceglia V, et al. 2022. Front Immunol. 12:786144. PubMed

Majority of thymocytes, T cell subset

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.